{"url_path":"/sec/pali/8-k/2026-06-11/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1357459/0001493152-26-028322-index.html","accession_number":"0001493152-26-028322","cik":"0001357459","ticker":"PALI","issuer_name":"PALISADE BIO, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1357459/0001493152-26-028322-index.html","primary_entity_key":"0001357459","primary_entity_name":"PALISADE BIO, INC."},"word_count":583,"has_tables":true,"body_markdown":"**Item\n5.07**\n**Submission\nof Matters to a Vote of Security Holders**\n\n \n\n*Annual\nMeeting of Stockholders*\n\n \n\nOn\nJune 10, 2026, the Company held its 2026 annual meeting of stockholders (the “Annual Meeting”). As of April 15, 2026, the\nrecord date for the Annual Meeting (“Record Date”), 167,424,202 shares of the Company’s common stock were outstanding\nand entitled to vote at the Annual Meeting. A summary of the matters voted upon by the stockholders at the Annual Meeting is set forth\nbelow.\n\n \n\nA\ntotal of 129,904,054 shares of the Company’s common stock were present in person or by proxy at the Annual Meeting, which represented\napproximately 77.59% of the shares of the Company’s common stock outstanding as of the Record Date, and constituted a quorum.\n\n \n\n**Proposal\n1.**\n\n** **\n\n**Election\nof Directors.**\n\n \n\nThe\nCompany’s stockholders elected the four (4) persons listed below as directors, each to serve until the Company’s 2027 annual\nmeeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.\nThe final voting results were as follows:\n\n \n\nName \nVotes For  \nVotes Withheld  \nBroker Non-Votes \n\nJ.D. Finley \n 106,600,509  \n 2,266,840  \n 21,036,704 \n\nDonald Williams \n 78,962,735  \n 29,904,615  \n 21,036,704 \n\nEmil Chuang \n 99,500,152  \n 9,367,198  \n 21,036,704 \n\nRobert F. Baltera, Jr. \n 108,502,141  \n 365,209  \n 21,036,704 \n\n \n\n**Proposal\n2.**\n\n** **\n\n**Ratification\nof the Selection of Independent Registered Public Accounting Firm.**\n\n \n\nThe\nCompany’s stockholders ratified the selection of Baker Tilly US, LLP as the Company’s independent registered public accounting\nfirm for the fiscal year ending December 31, 2026. The final voting results were as follows:\n\n \n\nVotes For  \nVotes Against  \nVotes Withheld / Abstentions  \nBroker Non-Votes \n\n129,320,182  \n 34,669  \n 549,203  \n - \n\n \n\n**Proposal\n3.**\n\n \n\n**Approval\nof an Amendment to the Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock.**\n\n** **\n\nThe\nCompany’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase\nthe number of authorized shares of common stock from 300,000,000 to 450,000,000 (which will result in an increase in the total number\nof authorized shares of capital stock of the Company from 307,000,000 to 457,000,000). The final voting results were as follows:\n\n \n\nVotes For  \nVotes Against  \nVotes Withheld / Abstentions  \nBroker Non-Votes \n\n128,093,623  \n 871,548  \n 938,883  \n - \n\n \n\n**Proposal\n4.**\n\n \n\n**Approval\nof the Amended and Restated Palisade Bio, Inc. 2021 Equity Incentive Plan.**\n\n \n\nThe\nCompany’s stockholders approved the Amended and Restated Palisade Bio, Inc. 2021 Equity Incentive Plan. The final voting results\nwere as follows:\n\n \n\nVotes For  \nVotes Against  \nVotes Withheld / Abstentions  \nBroker Non-Votes \n\n92,245,546  \n 14,658,772  \n 1,963,032  \n 21,036,704 \n\n \n\n \n\n \n\n \n\n**Proposal\n5.**\n\n \n\n**Approval\nof the Amended and Restated Palisade Bio, Inc. 2021 Employee Stock Purchase Plan.**\n\n \n\nThe\nCompany’s stockholders approved the Amended and Restated Palisade Bio, Inc. 2021 Employee Stock Purchase Plan. The final voting\nresults were as follows:\n\n \n\nVotes For  \nVotes Against  \nVotes Withheld / Abstentions  \nBroker Non-Votes \n\n108,167,158  \n 162,907  \n 537,285  \n 21,036,704 \n\n \n\n**Proposal\n6.**\n\n \n\n**Approval,\non a non-binding advisory basis, of the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement.**\n\n \n\nThe\nCompany’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed\nin the Proxy Statement. The final voting results were as follows:\n\n \n\nVotes For  \nVotes Against  \nVotes Withheld / Abstentions  \nBroker Non-Votes \n\n75,273,044  \n 31,773,692  \n 1,820,614  \n 21,036,704 \n\n \n\nAccordingly,\nthe Board will take these results under advisement.\n\n \n\n**Proposal\n7.**\n\n \n\n**Approval\nof equity award grants to our non-employee directors.**\n\n \n\nThe\nCompany’s stockholders approved equity grants to the Company’s non-employee directors. The final voting results were as follows:\n\n \n\nVotes For  \nVotes Against  \nVotes Withheld / Abstentions  \nBroker Non-Votes \n\n82,713,960  \n 24,332,309  \n 1,821,081  \n 21,036,704"}